Literature DB >> 28289795

[Pharmacological treatment of motor symptoms in Parkinson's diseases].

W H Jost1.   

Abstract

Since the 1960s many substance classes have been introduced for treatment of idiopathic Parkinson's disease. The most important and effective medication is levodopa (L-dopa) always in combination with a decarboxylase inhibitor. In addition, dopamine agonists, monoamine oxidase B (MAO-B) inhibitors, catechol-o-methyltransferase (COMT) inhibitors, N‑methyl-D-aspartate (NMDA) antagonists and very rarely anticholinergics are administered depending on the motor symptoms, age and a multitude of other factors. Fortunately, within the substance classes there are various preparations, which also have different effects. In order that the advantages of the individual medications can be exploited and undesired effects and interactions can be avoided, one must come to terms with the complex data and the pharmacology of the medication. In addition important aspects are interactions and reciprocal actions. In the foreseeable future, different substance classes are to be expected.

Entities:  

Keywords:  Catechol-o-methyltransferase inhibitor; Dopamine agonists; L-dopa; Monoamine oxidase B inhibitor; Pharmacology

Mesh:

Substances:

Year:  2017        PMID: 28289795     DOI: 10.1007/s00115-017-0309-z

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  89 in total

1.  Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.

Authors:  P Del Dotto; N Pavese; G Gambaccini; S Bernardini; L V Metman; T N Chase; U Bonuccelli
Journal:  Mov Disord       Date:  2001-05       Impact factor: 10.338

2.  A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.

Authors: 
Journal:  Arch Neurol       Date:  2002-12

Review 3.  Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.

Authors:  Anthony H V Schapira
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

Review 4.  The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.

Authors:  Susan H Fox; Regina Katzenschlager; Shen-Yang Lim; Bernard Ravina; Klaus Seppi; Miguel Coelho; Werner Poewe; Olivier Rascol; Christopher G Goetz; Cristina Sampaio
Journal:  Mov Disord       Date:  2011-10       Impact factor: 10.338

5.  Long-term effects of rasagiline and the natural history of treated Parkinson's disease.

Authors:  Olivier Rascol; Robert A Hauser; Fabrizio Stocchi; Cheryl J Fitzer-Attas; Yulia Sidi; Victor Abler; C Warren Olanow
Journal:  Mov Disord       Date:  2016-10       Impact factor: 10.338

6.  Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET.

Authors:  J S Fowler; R R MacGregor; A P Wolf; C D Arnett; S L Dewey; D Schlyer; D Christman; J Logan; M Smith; H Sachs
Journal:  Science       Date:  1987-01-23       Impact factor: 47.728

7.  Duodenal levodopa infusion in Parkinson's disease--long-term experience.

Authors:  D Nilsson; D Nyholm; S M Aquilonius
Journal:  Acta Neurol Scand       Date:  2001-12       Impact factor: 3.209

8.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

9.  The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.

Authors:  Alexandre Castro-Caldas; Paul Delwaide; Wolfgang Jost; Marcelo Merello; Adrian Williams; Paolo Lamberti; Miguel Aguilar; Susanna Del Signore; Pierre Cesaro
Journal:  Mov Disord       Date:  2006-04       Impact factor: 10.338

10.  Selegiline slows the progression of the symptoms of Parkinson disease.

Authors:  S Pålhagen; E Heinonen; J Hägglund; T Kaugesaar; O Mäki-Ikola; R Palm
Journal:  Neurology       Date:  2006-03-15       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.